中国生化药物杂志2017,Vol.37Issue(3) :267-269.DOI:10.3969/j.issn.1005-1678.2017.03.083

环磷酰胺联合VAD方案治疗多发性骨髓瘤的临床效果及对患者凝血功能的影响

Curative efficacy of cyclophosphamide combined with VAD regimen in treatment of multiple myeloma and its effects on coagulation function

许永萍 陈刚 张秦
中国生化药物杂志2017,Vol.37Issue(3) :267-269.DOI:10.3969/j.issn.1005-1678.2017.03.083

环磷酰胺联合VAD方案治疗多发性骨髓瘤的临床效果及对患者凝血功能的影响

Curative efficacy of cyclophosphamide combined with VAD regimen in treatment of multiple myeloma and its effects on coagulation function

许永萍 1陈刚 1张秦1
扫码查看

作者信息

  • 1. 武警浙江省总队嘉兴医院血液科,浙江嘉兴314000
  • 折叠

摘要

目的 研究环磷酰胺联合VAD方案治疗多发性骨髓瘤的临床效果及对患者凝血功能的影响.方法 选取2013年7月~2016年7月武警浙江省总队嘉兴医院接诊的78例多发性骨髓瘤患者,随机分为对照组和观察组,对照组采用VAD方案治疗,观察组采用环磷酰胺联合VAD方案治疗,观察2组患者治疗前后凝血因子及抗凝因子活性,不良反应情况及治疗效果.结果 治疗后,2组患者凝血因子Ⅱ均下降,蛋白C、蛋白S、抗凝血酶均上升,差异无统计学意义;观察组不良反应总发生率小于对照组[15.38%(6/39)vs 46.15%(18/39)],差异具有统计学意义(P<0.05);观察组总有效率显著高于对照组[89.74%(35/39)vs58.97%(23/39)],差异具有统计学意义(P<0.05).结论 环磷酰胺联合VAD方案治疗多发性骨髓瘤的临床显著,可有效改善患者的病况,提高患者的生存质量,且不会对凝血功能造成较大的影响.

Abstract

Objective To study curative efficacy of cyclophosphamide combined with VAD regimen in treatment of multiple myeloma and its effects on coagulation function.Methods 78 patients of multiple myeloma who received therapy from July 2013 to July 2016 in our hospital were selected as research objects, and divided into the control group and the observation group , the control group was treated with VAD regimen, while the observation group was treated with cyclophosphamide combined with VAD regimen.Then coagulation factor and anti-coagulation factor activity, adverse reaction, therapeutic effect after treatment between two groups were compared.Results After treatment, decreased blood coagulation factor, Protein C, protein S and antithrombin were increased between two groups , the difference was not statistically significant.Incidence of adverse reactions in observation group was less than the control group[15.38%(6/39)vs 46.15%(18/39)], the difference was statistically significant(P<0.05);The total effective rate of observation group was statistically higher than that in the control group [ 89.74%( 35/39 ) vs 58.97%( 23/39 ) ] , the difference was statistically significant(P<0.05).Conclusion Cyclophosphamide combined with VAD regimen is well for multiple myeloma, which can effectively improve the patient's condition, improve the life quality of patients, and will not cause a greater impact on blood coagulation function.

关键词

环磷酰胺/VAD方案/多发性骨髓瘤/临床效果/凝血功能

Key words

cyclophosphamide/VAD regimen/multiple myeloma/clinical effect/coagulation function

引用本文复制引用

出版年

2017
中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
被引量4
参考文献量11
段落导航相关论文